NACDS PRESIDENT AND CEO BOLGER WILL STAY UNTIL 1989
NACDS PRESIDENT AND CEO BOLGER WILL STAY UNTIL 1989 at the request of the Natl. Assn. of Chain Drug Stores' executive cmte. and board. Robert Bolger, who has headed the association for 19 years, announced his retirement plans last September ("The Pink Sheet" Sept. 16, T&G-1). Bolger had planned to retire in December 1987 after phasing-in his successor, who was expected to be brought on board in August 1986. The selection cmte. to find a successor to Bolger has been disbanded, although NACDS will continue to search for a successor informally. Bolger will remain closely involved in the search. With the turnover in D.C. health association leadership during the last several years, Bolger's presence at the head of NACDS has added continuity to the health care area. NACDS Chairman Alex Grass commented in a June 12 press release that the executive cmte. "will continue to periodically review candidates for the position of NACDS president and CEO in order to provide for a smooth transition during Bob Bolger's tentative departure in 1989." Under Bolger, NACDS has recently been a major force in the effort to change the Medicaid Rx drug reimbursement system. The assn. has been in close contact with the Health Care Financing Administration on proposed changes, and has been a leading voice behind such proposed modifications as the CIP, marketplace reimbursement system and implementation of a voucher-based collection system. Bolger's decision to remain with NACDS will allow the assn. to concentrate its efforts on trying to effect changes in the reimbursement system.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth